External Scientific Committee Biographies
Mark Chee, Ph.D.
Dr. Chee is the Chief Executive Officer and Chief Scientific Officer of Prognosys Biosciences, Inc., La Jolla, Calif. Previously, he was a co-founder of Illumina, Inc., San Diego, Calif., and senior scientist at Affymetrix, Inc. in Santa Clara, Calif. Dr. Chee is an advisor to the National Institutes of Health (NIH), serving on the National Advisory Council for Human Genome Research. He also serves on the editorial board of the journal, Genome Research.
William S. Dalton, M.D., Ph.D.
Dr. Dalton is President and Chief Executive Officer and Center Director of the Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa, Fla. He has been involved in cancer research for two decades and serves, or has served, on the editorial boards of Clinical Cancer Research, Molecular Cancer Therapeutics, Archives of Internal Medicine, Leukemia, American Journal of Oncology Review and Investigational New Drugs.
Lynn G. Dressler, Dr.P.H.
Dr. Dressler is an Assistant Professor in the Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, and serves as Associate Director of Ethics and Policy in the Institute of Pharmacogenomics and Individualized Therapy at University of North Carolina (UNC), Chapel Hill, N.C. Dr. Dressler is currently the principle investigator of UNC’s Center of Excellence in Ethical, Legal and Social Implications Research, supported by the National Human Genome Research Institute (NHGRI).
Geoffrey Duyk, M.D., Ph.D.
Dr. Duyk serves as Managing Director of Texas Pacific Group (TPG) Ventures, Menlo Park, Calif. Before joining TPG, he served on its board of directors and was president of research and development at Exelixis. Dr. Duyk was also among the founding scientific staff at Millennium Pharmaceuticals and eventually assumed the role of vice president of genetics. He has been and continues to be a member of numerous NIH panels and oversight committees focused on the planning and execution of the Human Genome Project.
David E. Housman, Ph.D.
Dr. Housman is the Ludwig Professor of Biology at the Massachusetts Institute of Technology, Cambridge, Mass., as well as an Associate in Neurology and Genetics at Massachusetts General Hospital in Boston, Mass. He is a member of both the National Academy of Sciences and the Institute of Medicine of the National Academies and has served on many advisory boards including those of the NHGRI, Merck Genome Project, and NCI Board of Scientific Counselors.
Chanita Hughes-Halbert, Ph.D.
Dr. Hughes-Halbert is an Associate Professor in the Department of Psychiatry and Director of the Community and Minority Cancer Control Program at the University of Pennsylvania, Philadelphia, Pa. Currently, she is a principal investigator of the NCI-funded West Philadelphia Consortium to Address Disparities; co-principal investigator of the NCI-funded Penn Center for Population Health and Health Disparities; and principal investigator for a project on Determinants of Ethnic Differences in Quality of Life within the Penn Center for Population Health.
Bruce E. Johnson, M.D.
Dr. Johnson is Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, Mass. He leads the Lung Cancer Program for the seven Harvard Medical School affiliated institutions and serves as an Associate Professor of Medicine at Brigham and Women’s Hospital and Harvard Medical School in Boston, Mass. Dr. Johnson serves on the editorial boards of the Journal of Clinical Oncology, International Journal of Oncology, among others.
Susan M. Love, M.D.
Dr. Love is President and Medical Director of the Dr. Susan Love Research Foundation in Santa Barbara, Calif., a nonprofit organization dedicated to the eradication of breast cancer. She is one of the founders of the breast cancer advocacy movement and continues this work by serving on the boards of the National Breast Cancer Coalition and Medical Advisory Board of Young Survival Coalition. She is a Clinical Professor of Surgery at the David Geffen School of Medicine at the University of California Los Angeles and serves as a member of the National Cancer Advisory Board.
Frank McCormick, Ph.D.
Dr. McCormick is Director of the Helen Diller Family Comprehensive Cancer at the University of California of San Francisco (UCSF), Calif. He holds the David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research, is a professor in the Department of Microbiology and Immunology, and Associate Dean of the UCSF School of Medicine. Dr. McCormick is founder of Onyx Pharmaceuticals, where he developed a life-saving drug for treatment of kidney and liver cancer.
Jennifer A. Pietenpol, Ph.D.
Dr. Pietenpol is Director of the Vanderbilt-Ingram Cancer Center, B.F. Byrd, Jr., Professor of Oncology, and Professor of Biochemistry at the Vanderbilt University Medical Center, Nashville, Tenn. She is a member of several review panels at the NIH, American Cancer Society, and Susan G. Komen Breast Cancer Foundation. Since 2002, she has served as the chair of the American Cancer Society Institutional Review Group. She is currently an associate editor for the journals Cancer Research and Cell Cycle and is also on the editorial board for several other journals including, Journal of Biological Chemistry, Breast Cancer Research, among others. She also serves as a member of the National Cancer Advisory Board.
George W. Sledge, Jr., M.D.
Dr. Sledge is the Ballvé-Lantero Professor of Oncology at Indiana University at Indianapolis, Ind., where he co-directs Indiana University Simon Cancer Center's breast cancer program. He currently serves as chair of the Eastern Cooperative Oncology Group's Breast Cancer Committee, and is a member of the American Society of Clinical Oncology's Board of Directors. Dr. Sledge also serves on the advisory board of the Triple-Negative Breast Cancer Foundation.
Louis M. Staudt, M.D., Ph.D.
Dr. Staudt is the Deputy Chief of the Metabolism Branch as well as Co-Director of the Lymphoma/Leukemia Molecular Profiling Project (LLMPP), a multi-institutional consortium that aims to develop a new molecular framework for the diagnosis of all lymphoid malignancies. He also serves on the Editorial Boards of Cancer Cell and The Journal of Experimental Medicine. In 2009, he received Dameshek Prize from the American Society of Hematology for outstanding contribution in hematology and in 2011 received the honorary title of NIH Distinguished Investigator.
Robert H. Waterston, M.D., Ph.D.
Dr. Waterston is Professor and Chair of Genome Sciences at the University of Washington, Seattle, Wash. He is an internationally noted scientific leader and one of the early architects of gene mapping and DNA sequencing. He is also a member of the National Academy of Sciences.